FindTrial
Sign In

Clinical application of rapid mass spectrometry to detect metabolites in the intraoperative diagnosis of IDH mutation in glioma

Clinical application of rapid detection of metabolites in the intraoperative diagnosis of glioma

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100044931
Enrollment
Unknown
Registered
2021-03-31
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

status&#32
by&#32
detecting&#32
the&#32
ratio&#32
of&#32
2HG&#32
to&#32
GA&#32
in&#32
tumor&#32
IDH&#32
gene&#32
mutation&#32
Gold Standard:IDH Mutations Sequencing.
Index test:Intraoperative&#32
rapid&#32
mass&#32
spectrometry&#32
identifies&#32

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are initially diagnosed with glioma before surgery and require surgical resection and biopsy.

Exclusion criteria

Exclusion criteria: 1.Patients with severe cardiopulmonary insufficiency; 2.Patients with coagulation dysfunction; 3.Unconscious patients.

Design outcomes

Primary

MeasureTime frame
2-hydroxyglutaric acid/glutamic acid;SEN, SPE, ACC, AUC of ROC;—

Countries

China

Contacts

Public ContactHua Wei

Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai

hs_glioma@126.com+86 15800589540

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026